Modulation of the neuroendoctrine system as a therapy for motor neuron disease
US7572596B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 2, 2005 |
| Grant date | Aug 11, 2009 |
| Priority date | — |
| Expiry date | Apr 13, 2026 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/25
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.